In contrast, miR-221 inhibits tumor progression in diseases such as pancreatic and ovarian cancers, by targeting factors, such as SOCS3 and ADP-ribosylation factor-4 (ARF4) [11, 49]. Here, ARF4 is linked to ovarian carcinoma.